Piramal Pharma Invests US$90 Million to Expand Manufacturing Facilities in Kentucky and Michigan, USA
Introduction:
Piramal Pharma plans to invest US$90 million to expand two pharmaceutical manufacturing facilities located in Lexington, Kentucky and Riverview, Michigan, USA.
Features:
The facility in Lexington, Kentucky, will be expanded to include 24,000 square feet of new manufacturing space and a laboratory to support the production of sterile injectable drug products.
Additions to the Lexington site include a new liquid filling line, two large-scale lyophilizers, an external vial washer, and a capping machine.
The Michigan facility, located in Riverview, will add a dedicated facility for the development and manufacturing of payload-linkers used in bioconjugates such as antibody-drug conjugates (ADCs).
The new suite at the Michigan site is designed for handling high-potency compounds and is expected to be operational by the end of 2025.
Both sites will be integrated into broader manufacturing workflows to support end-to-end production of complex drug products, including bioconjugates and sterile injectables.
The Lexington facility expansion is scheduled for completion by late 2027, while the Riverview suite is expected to be online before the end of 2025.
Specifications:
| Name | Piramal Pharma Limited |
| Type | New Construction |
| Budget | US$90 million |
| Year | 2025 and 2027 |
